Cargando…

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease

Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack the ability to make functional immunoglobulin require life-long replacement therapy to prevent serious bacterial infections. Human serum immunoglobulin manufactured from pools of dona...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoda-Smith, Suzanne, Torgerson, Troy R, Ochs, Hans D
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817783/
https://www.ncbi.nlm.nih.gov/pubmed/20169031
_version_ 1782177243112407040
author Skoda-Smith, Suzanne
Torgerson, Troy R
Ochs, Hans D
author_facet Skoda-Smith, Suzanne
Torgerson, Troy R
Ochs, Hans D
author_sort Skoda-Smith, Suzanne
collection PubMed
description Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack the ability to make functional immunoglobulin require life-long replacement therapy to prevent serious bacterial infections. Human serum immunoglobulin manufactured from pools of donated plasma can be administered intramuscularly, intravenously or subcutaneously. With the advent of well-tolerated preparations of intravenous immunoglobulin (IVIg) in the 1980s, the suboptimal painful intramuscular route of administration is no longer used. However, some patients continued to experience unacceptable adverse reactions to the intravenous preparations, and for others, vascular access remained problematic. Subcutaneously administered immunoglobulin (SCIg) provided an alternative delivery method to patients experiencing difficulties with IVIg. By 2006, immunoglobulin preparations designed exclusively for subcutaneous administration became available. They are therapeutically equivalent to intravenous preparations and offer patients the additional flexibility for the self-administration of their product at home. SCIg as replacement therapy for patients with primary antibody deficiencies is a safe and efficacious method to prevent serious bacterial infections, while maximizing patient satisfaction and improving quality of life.
format Text
id pubmed-2817783
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28177832010-02-18 Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease Skoda-Smith, Suzanne Torgerson, Troy R Ochs, Hans D Ther Clin Risk Manag Review Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack the ability to make functional immunoglobulin require life-long replacement therapy to prevent serious bacterial infections. Human serum immunoglobulin manufactured from pools of donated plasma can be administered intramuscularly, intravenously or subcutaneously. With the advent of well-tolerated preparations of intravenous immunoglobulin (IVIg) in the 1980s, the suboptimal painful intramuscular route of administration is no longer used. However, some patients continued to experience unacceptable adverse reactions to the intravenous preparations, and for others, vascular access remained problematic. Subcutaneously administered immunoglobulin (SCIg) provided an alternative delivery method to patients experiencing difficulties with IVIg. By 2006, immunoglobulin preparations designed exclusively for subcutaneous administration became available. They are therapeutically equivalent to intravenous preparations and offer patients the additional flexibility for the self-administration of their product at home. SCIg as replacement therapy for patients with primary antibody deficiencies is a safe and efficacious method to prevent serious bacterial infections, while maximizing patient satisfaction and improving quality of life. Dove Medical Press 2010 2010-02-02 /pmc/articles/PMC2817783/ /pubmed/20169031 Text en © 2010 Skoda-Smith et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Skoda-Smith, Suzanne
Torgerson, Troy R
Ochs, Hans D
Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
title Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
title_full Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
title_fullStr Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
title_full_unstemmed Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
title_short Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
title_sort subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817783/
https://www.ncbi.nlm.nih.gov/pubmed/20169031
work_keys_str_mv AT skodasmithsuzanne subcutaneousimmunoglobulinreplacementtherapyinthetreatmentofpatientswithprimaryimmunodeficiencydisease
AT torgersontroyr subcutaneousimmunoglobulinreplacementtherapyinthetreatmentofpatientswithprimaryimmunodeficiencydisease
AT ochshansd subcutaneousimmunoglobulinreplacementtherapyinthetreatmentofpatientswithprimaryimmunodeficiencydisease